Skip to main content
Log in

Hormone und Karzinogenese beim Mammakarzinom

Hormones and carcinogenesis in breast cancer

  • Menopause und Frauengesundheit
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Hintergrund

In epidemiologischen Studien zeigt sich, dass die Pathogenese des Mammakarzinoms ein multifaktorielles Geschehen ist. Weltweit erkrankt jede achte bis zehnte Frau im Laufe ihres Lebens, was den hohen Stellenwert dieser Erkrankung unterstreicht.

Bedeutung der Östrogenexposition

Die Vermutung, dass eine endogene oder exogene Östrogenexposition Einfluss auf die Genese des Mammakarzinoms hat, besteht seit Ende des 19. Jahrhunderts. Die Hormonersatztherapie wird so kontrovers diskutiert wie kaum ein anderes Thema in der Gynäkologie. Im Folgenden wird ein kurzer Überblick über die Grundlagen der Hormonersatztherapie gegeben, um dann detaillierter auf die Karzinogenese des Mammakarzinoms und den, trotz der Limitationen im Studiendesign, weiterhin hohen Stellenwert der Women’s-Health-Initiative(WHI)-Studie einzugehen.

Einfluss von Prolaktin

Die Auswirkungen des Prolaktinspiegels auf die Entwicklung des Mammakarzinoms müssen in kommenden Studien noch eingehender untersucht werden.

Abstract

Background

Epidemiological studies have shown that the pathogenesis of breast cancer is multifactorial. Since women have a lifetime risk of 10 % to develop breast cancer, it is one of the most important female malignancies.

The significance of estrogen exposure

The hypothesis that endogenous or exogenous estrogen influences the genesis of breast cancer was first formulated in the late 1890s. The use of hormone replacement therapy is one of the most controversially discussed topics in gynecology. The present article provides a short overview of the principles of hormone replacement therapy in order to then focus on the carcinogenesis of breast cancer more closely, and discusses the particular relevance of the Women’s Health Initiative (WHI) study, despite limitations in the study design.

The role of prolactin

The influence of high serum prolactin on the development of breast cancer needs to be evaluated in further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Robert Koch-Institut. Krebs in Deutschland – Die Brustdrüse. Krebsregisterdaten des Robert Koch-Institutes. Stand 2012

  2. Beatson CT (1896) On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 148:162–165

    Article  Google Scholar 

  3. Chlebowski RT, Anderson GL (2012) Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104:517–527

    Google Scholar 

  4. Birkhauser MH, Panay N, Archer DF et al (2008) Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 11:108–123

    Article  PubMed  CAS  Google Scholar 

  5. Arzneimittelkommission der Deutschen Ärzteschaft (2003) Therapieempfehlung der Arzneimittelkommission der Deutschen Ärzteschaft zu „Hormontherapie im Klimakterium“. http://www.akdae.de/35/10/82_Hormontherapie_2003_1Auflage.pdf

  6. Eriksen EF (2012) Hormone replacement therapy or SERMS in the long term treatment of osteoporosis. Minerva Ginecol 64:207–221

    PubMed  CAS  Google Scholar 

  7. Ortmann O, Lattrich C (2012) The treatment of climacteric symptoms. Dtsch Arztebl Int 109:316–323

    PubMed  Google Scholar 

  8. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: prinicipal results from the Womens’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  9. Chlebowski RT, Anderson GL, Manson JE et al (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28:690–697

    Google Scholar 

  10. Eden JA (2011) Breast cancer, stem cells and sex hormones. Part 3: the impact of the menopause and hormone replacement. Maturitas 68:129–136

    Article  PubMed  CAS  Google Scholar 

  11. Chlebowski RT, McTiernan A, Aragaki AK et al (2011) Metformin and breast cancer incidence in postmenopausal diabetic women in the Women’s Health Initiative (WHI). J Clin Oncol 29 (Suppl): Abstract 1503

    Google Scholar 

  12. Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582–3590

    Google Scholar 

  13. Chlebowski RT, Anderson GL (2012) Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104:517–527

    Google Scholar 

  14. Beckmann KR, Farshid G, Roder DM et al (2013) Impact of hormone replacement therapy use on mammographic screening outcomes. Cancer Causes Control 24:1417–1426

    Article  PubMed  Google Scholar 

  15. Das R, Vonderhaar BK (1997) Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 2:29–39

    Google Scholar 

  16. Tworoger SS, Sorensen B, Chubak J et al (2007) Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 16:895–899

    Article  PubMed  CAS  Google Scholar 

  17. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25:1482–1488

    Google Scholar 

  18. Campagnoli C, Pasanisi P, Castellano I et al (2013) Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Res Treat 139:1–11

    Article  PubMed  CAS  Google Scholar 

  19. Macedo LF, Guo Z, Tilghman SL et al (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66:7775–7782

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. M. Falkenberg und L. Kiesel geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Falkenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falkenberg, M., Kiesel, L. Hormone und Karzinogenese beim Mammakarzinom. Gynäkologische Endokrinologie 11, 225–228 (2013). https://doi.org/10.1007/s10304-013-0567-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-013-0567-1

Schlüsselwörter

Keywords

Navigation